Myriad Genetics | MYGN - Debt


Myriad Genetics reported $59.3M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Agilent USD 3.35B 55M Sep/2025
Becton, Dickinson and Co. USD 19.54B 358M Dec/2025
Bio-Rad Laboratories USD 1.4B 11.2M Sep/2025
Bruker USD 2.01B 426.8M Sep/2025
Danaher USD 18.48B 66M Mar/2026
Illumina USD 2.58B 22M Sep/2025
J&J USD 47.93B 2.14B Dec/2025
Mettler Toledo International USD 2.21B 25.94M Sep/2025
Myriad Genetics USD 59.3M 19.7M Mar/2025
OraSure Technologies USD 782K 465K Jun/2024
Pacific Biosciences Of California USD 892.24M 653K Dec/2023
Quest Diagnostics USD 6.41B 179M Mar/2026
Quidel USD 2.84B 51.1M Sep/2025
Repligen USD 542.21M 146.65M Dec/2025
Revvity USD 3.37B 5.86M Sep/2025
Standard Biotools USD 27.39M 1.23M Sep/2025
Thermo Fisher Scientific USD 39.39B 3.7B Dec/2025
Veracyte USD 40.45M 10.19M Sep/2025
Waters USD 1.49B 52.2M Sep/2025